Instrument Inactif

Communiqués BioAdaptives, Inc. Other OTC

Actions

BDPT

US09072U1079

Transformation des aliments

Communiqués

13/08	BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update	AQ
12/08	BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal	AQ
04/08	BioAdaptives Explains the Scientific Basis of the Dual-Action Xcellara(TM) "Supply and Direction" Platform	AQ
03/08	BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula	AQ
30/07	BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor	AQ
29/07	BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic Platform	AQ
23/07	BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches	AQ
16/07	BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness	AQ
15/07	BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells	AQ
25/06	BioAdaptives Completes MyndSystem™ Platform with TruShield Certification of MyndRenew™, Securing Full WADA Compliance for Professional Athletes and Expanding Market Opportunity	AQ
20/05	BioAdaptives Launches MyndSystem™ Website — The First Supplement Platform Designed to Support Both Daytime Cognitive Performance and Overnight Brain Recovery	AQ
06/05	BioAdaptives, Inc. Launches MyndRenew™ to Complete the 24-Hour Brain Performance Cycle	AQ
28/04	BioAdaptives introduces MyndSystem™, an integrated Neuro-Performance & Repair system for day and night	AQ
07/10/25	BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing	AQ
20/08/25	BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety	AQ
16/07/25	BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience	AQ
24/06/25	BioAdaptives Announces National Launch of Pawpa™ Regen	AQ
28/05/25	BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements	AQ
13/03/25	Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial	AQ
06/02/25	BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors	AQ
03/02/25	BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors	AQ
21/01/25	BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders	AQ
10/12/24	BioAdaptives, Inc. Launches Xcellara™ Stem Cell Activator – Harnessing Nature for Optimal Health	AQ
05/12/24	BioAdaptives : Board of Directors Approves a One for One Stock Dividend Form 8 K	PU
03/12/24	BioAdaptives, Inc.’s Board of Directors Approves a One-for-One Stock Dividend	AQ